ReferenceRRK4817

LEAP

A Phase IIa Randomised Double Blind Placebo-controlled Parallel Group Study to Assess the Safety and Efficacy of 28 Day Oral administration of BAY 85-8501 in Patients with no-Cystic Fibrosis Bronchiectasis

Research Summary

Research Overview
Project Status Open
Proposed End Date 30/08/2014
Study Run through CRF? No
Recruitment so far 0